A PYMNTS Company

US: More evidence surfaces against pay-for-delay

By  |  July 19, 2013
US: More evidence surfaces against pay-for-delay

A study commissioned by the Generic Pharmaceutical Association found that settlement payments from pay-for-delay cases result in positive effects for consumers, according to reports. The GPhA announced the findings of the study, performed by Intercontinental Marketing Services, at a press conference. The findings further back regulatory decisions by the US Federal Trade Commission and, more recently, the US Supreme Court, that backed the possibility that the so-called pay-for-delay agreements, which delay the sale of cheaper generic pharmaceuticals so brand names can remain on shelves, can be anticompetitive. Reports say the GPhA’s study found that consumers saved $25.5 billion between 2005 and 2012 through such settlements for 33 different pharmaceutical drugs.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Full Content: Patent Docs

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.